Liu W, et al. - In participants with ovarian cancer receiving chemotherapy with carboplatin, researchers assessed the impact of magnesium abnormalities on the survival. There were 229 patients with advanced ovarian cancer who had surgery and chemotherapy between January 1, 2004, and December 31, 2014 enrolled. They observed a significant association of higher baseline heart rate (beats per minute) and a higher frequency of hypomagnesemia during treatment with shorter survival. The relationship was independent of completeness of tumor reduction and International Federation of Gynecology and Obstetrics stage. Better strategies for managing hypomagnesemia is needed in this patient population.